Editor's Choice Can we tame the monster? BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7558.0-f (Published 06 July 2006) Cite this as: BMJ 2006;333:0-f Article Related content Metrics Responses Peer review Related articles Analysis And Comment Did regulators fail over selective serotonin reuptake inhibitors? Published: 06 July 2006; BMJ 333 doi:10.1136/bmj.333.7558.92 News Obesity is less common in richer countries Published: 29 June 2006; BMJ 333 doi:10.1136/bmj.333.7557.12 Letter Research for profit Published: 11 May 2006; BMJ 332 doi:10.1136/bmj.332.7550.1155-c See more Cancer drugs remain FDA approved despite lack of benefit, study finds BMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568 Johnson & Johnson is ordered to pay $1bn over faulty hip implants BMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Trial of novel leukaemia drug is stopped for second time after two more deaths BMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376 Promise of new Alzheimer’s drug is dashed after lack of evidence BMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362 Cited by... Why don't we have all the evidence on oseltamivir?Fulltext
